ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S

Reuters

07-30

ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S

ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration (FDA). IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of Instil Bio, Inc. As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on July 30, 2025, and is solely responsible for the information contained therein.

免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。

热议股票

1
2
3
4
5
6
7
8
9
10

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/news/2555593046"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental"},"__swrFallback__":{"@#url:\"https://stock-news.skytigris.cn/v3/news\",params:#id:\"2555593046\",edition:\"fundamental\",,,undefined,":{"share":"https://ttm.financial/m/news/2555593046?lang=zh_CN&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2025-07-30 19:37","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"2555593046","market":"fut","top_or_hot":-1,"title":"ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S","media":"Reuters","content":"<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration (FDA). IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of <a href=\"https://laohu8.com/S/TIL\">Instil Bio, Inc.</a> As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1032215980\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Reuters </p>\n<p class=\"h-time\">2025-07-30 19:37</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<html xmlns=\"http://www.w3.org/1999/xhtml\" xmlns:newsg2=\"http://iptc.org/std/nar/2006-10-01/\" xmlns:xhtml=\"http://www.w3.org/1999/xhtml\"><head><title>\n      ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S\n    </title></head><body><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<p>\n        ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration (FDA). IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of <a href=\"https://laohu8.com/S/TIL\">Instil Bio, Inc.</a> As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.\n      </p>\n</div><div xmlns:xsd=\"http://www.w3.org/2001/XMLSchema\" xmlns:xsi=\"http://www.w3.org/2001/XMLSchema-instance\">\n<em>Disclaimer: <span>This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on July 30, 2025, and is solely responsible for the information contained therein.</span></em>\n</div></body></html>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"01541","symbol_name":"宜明昂科-B","start_time":0,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20250730:nNDL3Gr3D0:1","article_id":"2555593046","we_media_id":"1032215980","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=2555593046","pubTimestamp":1753875436,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Reuters","introduction":"Reuters.com brings you the latest news from around the world, covering breaking news in markets, business, politics, entertainment and technology","home_visible":1,"id":"1032215980","head_image":"https://community-static.tradeup.com/news/4567337cbdf294b657b1fa87c5488b48"},"summary":"ImmuneOnco Biopharmaceuticals  Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration . IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of Instil Bio, Inc. As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or le","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"01541":"宜明昂科-B","TIL":"Instil Bio, Inc.","BK4505":"高瓴资本持仓","BK1161":"生物科技","BK4139":"生物科技"},"translate_title":"ImmuneOnco Biopharmaceuticals宣布FDA批准在美国启动IMM2510/AXN-2510的I期临床试验","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"01541":0.9,"TIL":0.9},"content_text":"ImmuneOnco Biopharmaceuticals Announces FDA Clearance to Initiate Phase I Clinical Trial for IMM2510/AXN-2510 in the U.S\n    \n\n        ImmuneOnco Biopharmaceuticals (Shanghai) Inc. has announced the initiation of a Phase I clinical trial for IMM2510/AXN-2510 in the United States, following clearance from the U.S. Food and Drug Administration (FDA). IMM2510/AXN-2510 is a PD-L1 and VEGF bispecific antibody currently under development. The trial's commencement marks a significant milestone in the company's collaboration with Axion Bio, a wholly-owned subsidiary of Instil Bio, Inc. As part of this development, ImmuneOnco has received a milestone payment of US$10 million from Instil Bio. To date, total payments under their License and Collaboration Agreement have reached US$30 million. Results from this trial are expected to be presented in the future.\n      \n\nDisclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Immuneonco Biopharmaceuticals (Shanghai) Co. Ltd. published the original content used to generate this news brief on July 30, 2025, and is solely responsible for the information contained therein.","kind":"highlight","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":null,"editions":null,"column":"","sentiment":"1","news_tag":"productRelease","news_rank":0,"symbols":[],"gpt_button":0,"code":"91000000","status":"200"}}}